Tom 14, Nr 1 (2019)
Artykuły
Opublikowany online: 2019-04-08
Wyświetlenia strony
517
Wyświetlenia/pobrania artykułu
1402
Stosowanie biwalirudyny u pacjentów z ostrym zespołem wieńcowym poddawanych przezskórnym interwencjom wieńcowym w Polsce: aktualizacja stanowiska ekspertów Asocjacji Interwencji Sercowo-Naczyniowych Polskiego Towarzystwa Kardiologicznego
Kardiol Inwazyjna 2019;14(1):34-40.
Streszczenie
Brak
Referencje
- Sanchis-Gomar F, Perez-Quilis C, Leischik R, et al. Epidemiology of coronary heart disease and acute coronary syndrome. Ann Transl Med. 2016; 4(13): 256.
- Wożakowska-Kapłon B, Lesiak M, Ochała A, et al. Bivalirudine use in the acute myocardial infarction in patients undergoing percutaneous coronary interventions: consensus statement of experts from the Cardiovascular Pharmacotherapy Working Group and the Association on Cardiovascular Interventions of the Polish Cardiac Society. Kardiol Pol. 2014; 72(8): 761–765.
- Valgimigli M, Frigoli E, Leonardi S, et al. Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. Lancet. 2018; 392(10150): 835–848.
- Shah R, Jovin IS, Chaudhry A, et al. Safety and efficacy of switching from unfractionated heparin to bivalirudin during primary percutaneous coronary intervention. Catheter Cardiovasc Interv. 2019; 93(2): 241–247.
- Anantha-Narayanan M, Anugula D, Gujjula NR, et al. Bivalirudin versus heparin in percutaneous coronary intervention-a systematic review and meta-analysis of randomized trials stratified by adjunctive glycoprotein IIb/IIIa strategy. J Thorac Dis. 2018; 10(6): 3341–3360.
- Grajek S, Michalak M, Gwizdała A, et al. Patients treated with bivalirudin are still at higher risk of stent thrombosis: a comprehensive meta-analysis of randomised clinical trials of bivalirudin and heparin for percutaneous coronary interventions. Kardiol Pol. 2018; 76(4): 740–749.
- Neumann FJ, Sousa-Uva M, Ahlsson A, et al. ESC Scientific Document Group , ESC Scientific Document Group . 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019; 40(2): 87–165.
- Kereiakes D, Yeh R, Massaro J. Stent thrombosis in drug-eluting or bare-metal stents in patients receiving dual antiplatelet therapy. JACC: Cardiovasc Interv. 2015; 8(12): 1552–1562.
- Kam PCA, Kaur N, Thong CL. Direct thrombin inhibitors: pharmacology and clinical relevance. Anaesthesia. 2005; 60(6): 565–574.
- Alquwaizani M, Buckley L, Adams C, et al. Anticoagulants: a review of the pharmacology, dosing, and complications. Curr Emerg Hosp Med Rep. 2013; 1(2): 83–97.
- Cannon CP, Maraganore JM, Loscalzo J, et al. Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease. Am J Cardiol. 1993; 71(10): 778–782.
- Stratmann G, deSilva AM, Tseng EE, et al. Reversal of direct thrombin inhibition after cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia. Anesth Analg. 2004; 98(6): 1635–9, table of contents.
- Valgimigli M, Frigoli E, Leonardi S, et al. MATRIX Investigators. Bivalirudin or unfractionated heparin in acute coronary syndromes. N Engl J Med. 2015; 373(11): 997–1009.
- Erlinge D, Koul S, Omerovic E, et al. Bivalirudin versus heparin monotherapy in myocardial infarction. N Engl J Med. 2017; 377(12): 1132–1142.
- Eikelboom JW, Connolly SJ, Bosch J. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017; 377 (14): 1319–1330.
- Mallifi JR, Lotfi AS. Management of STEMI in patients on NOACs and undergoing primary PCI. Expert analysis ACC website 2015. https://www.acc.org/latest-in-cardiology/articles/2015/.
- Witkowski A, Barylski M, Filipiak KJ, et al. Non-vitamin K antagonist oral anticoagulants (NOACs) in the treatment of coronary and peripheral atherosclerosis. Expert Consensus. Kardiol Pol. 2019 [Epub ahead of print].
- Wojtasik-Bakalarz J, Kleczyński P, Zasada W, et al. Safety of bivalirudin versus unfractionated heparin in endovascular revascularization of peripheral arteries in short- and long-term follow-up. Advances in Interventional Cardiology. 2019.
- Stone GW, Maehara A, Witzenbichler B, et al. INFUSE-AMI Investigators. Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. JAMA. 2012; 307(17): 1817–1826.
- Stone GW, Witzenbichler B, Guagliumi G, et al. HORIZONS-AMI Trial Investigators. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008; 358(21): 2218–2230.
- Stone G, McLaurin B, Cox D. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006; 355(21): 2203–2216 –2216.
- Steg PG, van 't Hof A, Hamm CW, et al. EUROMAX Investigators. Bivalirudin started during emergency transport for primary PCI. N Engl J Med. 2013; 369(23): 2207–2217.
- Wallentin L, Becker RC, Budaj A, et al. PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361(11): 1045–1057.
- Wiviott SD, Braunwald E, McCabe CH, et al. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007; 357(20): 2001–2015.
- Koster A, Faraoni D, Levy JH. Argatroban and bivalirudin for perioperative anticoagulation in cardiac surgery. Anesthesiology. 2018; 128(2): 390–400.
- Schwenkglenks M, Toward T, Plent S, et al. Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction. Heart. 2012; 98(7): 544–551.
- Borg S, Persson U, Allikmets K, et al. Comparative cost-effectiveness of anticoagulation with bivalirudin or heparin with and without a glycoprotein IIb/IIIa-receptor inhibitor in patients undergoing percutaneous coronary intervention in Sweden: a decision-analytic model. Clin Ther. 2006; 28(11): 1947–1959.
